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Among 152600 breast cancer patients diagnosed during 1958–2000, there was a 22% increased risk of developing a second primary
non-breast malignancy (standardised incidence ratio (SIR)¼1.22; 95% confidence interval (CI): 1.19–1.24). The highest risk was seen
for connective tissue cancer (SIR¼1.78; 95% CI: 1.49–2.10). Increased risks were noted among women diagnosed with breast
cancer before age 50. Oesophagus cancer and non-Hodgkin’s lymphoma showed six- and four-fold higher risks, respectively, in
women with a family history of breast cancer compared to those without in the X10-year follow-up period.
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With advances in early diagnosis and treatment, for many women
breast cancer is becoming increasingly curable. Breast cancer
survivors have been reported as having a 10–60% increased risk of
a second primary malignancy at other sites compared to the
general population (Mellemkjaer et al, 2006; Raymond and Hogue,
2006; Yu et al, 2006). Multiple primary tumours may be caused by
shared aetiological factors (e.g. diet, reproductive history, hormo-
nal status, and environmental exposure), inherited susceptibility,
adverse effects of treatment, increased medical surveillance, and
possible interactions between these factors (Travis, 2002; Suzuki
et al, 2005). Up to 7% of breast cancer cases are estimated to be
due to breast cancer susceptibility genes (e.g. BRCA1, BRCA2, p53,
and PTEN) (Edlich et al, 2005), adding to the risk of other cancers
(Edlich et al, 2005; McClain et al, 2005).
Most breast cancer patients will die of causes other than breast
cancer; so the long-term effects of treatment have become
correspondingly important (Shapiro and Recht, 1994). Increased
risks of soft tissue sarcomas (Karlsson et al, 1998; Levi et al, 2003),
lung (Prochazka et al, 2002, 2005), and oesophageal cancer
(Zablotska et al, 2005) have been associated with radiotherapy of
the breast. In addition, a causal relationship between tamoxifen
and endometrial cancer risk has been established (Bergman et al,
2000; Swerdlow and Jones, 2005).
We aimed to examine the risk of second malignancies in women
with breast cancer, according to age at and time interval since
breast cancer diagnosis, and calendar period. In addition, we
investigated the effect of family history of breast cancer.
MATERIALS AND METHODS
Eligible patients included 171386 women with histologically
confirmed invasive breast cancer as the first cancer reported to
the Swedish Cancer Registry between 1958 and 2000. The Swedish
Cancer Registry receives reports on newly diagnosed cancers from
both pathologists/cytologists and physicians. Reporting to the
register is compulsory, and 96% of all cancers in Sweden are
reported (Mattsson and Wallgren, 1984). Almost all diagnosed
breast cancer patients in Sweden are treated within the national
health care system and treatment regimens are similar throughout
the country.
The breast cancer cohort was matched with the Swedish
Emigration and Cause of Death Registries. Excluded were women
diagnosed with a second cancer (n¼7370) or dying (n¼3547)
within 1 month after the first primary cancer. Additional
exclusions included women identified as immigrants as data on
previous cancers were unavailable, and women who had emigrated
before the diagnosis of breast cancer and left Sweden for X1year
(n¼7883). Thus, 152586 women were included in the study. A
four-digit diagnostic code according to the seventh revision of
the International Classification of Diseases (ICD-7) was used. The
following ICD-7 codes were pooled: ‘upper aerodigestive tract’,
codes 140–141, 143–148, and 161; ‘colorectum’, codes 153–154;
‘liver’, codes 155–156; ‘non-Hodgkin’s lymphoma’, codes 200 and
202; and ‘leukaemia’, codes 204–207.
Our database for analysis of risk for second primary malig-
nancies according to family history of breast cancer was created
by a link between the Cancer Registry from 1958 to 2000 and
Multigeneration Register using the individually unique national
registration number. Statistics Sweden maintains a Multigenera-
tion Register where offspring born in Sweden in 1932 and later are
registered with their biological parents as families (Hemminki
et al, 2001). At present, it includes 11 million individuals, who are
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ystructured in 3.1 millions of nuclear families. Breast cancer history
was collected on all first-degree relatives, namely parents, siblings,
and offspring, and if positive, this is described in this paper as
‘with a family history’.
Statistical methods
Standardised incidence ratios (SIRs) were calculated by dividing
the observed number of second primary cancers by the number
expected based on population rates. The observed number of cases
was assumed to be Poisson distributed, and 95% confidence
intervals (CIs) for SIR were calculated (Breslow and Day, 1987).
Person years at risk were calculated as starting at date of breast
cancer diagnosis and ending at date of death, emigration, second
primary cancer diagnosis, or 31 December 2000, whichever date
came first. The expected number of cancers was estimated by
multiplying the age-, sex-, and calendar year-specific rates from
the Swedish Cancer Registry by the accumulated person years at
risk. The follow-up period was divided into 1–9 years and 10 or
more years after breast cancer diagnosis. The all sites SIRs
combine the specific cancer sites presented in each table.
The SIRs for second primary malignancies according to family
history of breast cancer were calculated similarly, except that the
expected numbers of cancers were obtained using age-, sex-, and
calendar year-specific rates in the corresponding general popula-
tion in our database. The ratio of SIR with a family history to SIR
without a family history was calculated to easily compare these two
groups, and 95% CIs were estimated (Clayton and Hill, 1993).
Similarly, the ratio of SIR for women o50 years of age at breast
cancer diagnosis to that X50 years was calculated.
RESULTS
Table 1 presents SIRs by specific sites of subsequent cancers. A 22%
increased risk of a second primary malignancy other than breast
cancer was found. The largest significant excess risk was found for
connective tissue cancer (SIR¼1.78; 95% CI: 1.49–2.10). In
addition, we investigated cancer sites stratified by time since breast
cancer diagnosis, 1–9 and X10 years (data not shown). Sites with
SIRs that were significantly higher for the longer follow-up period
were lung cancer (SIR¼1.00, 95% CI¼0.89–1.11, n¼316 vs
SIR¼1.92, 95% CI¼1.74–2.12, n¼401) and non-Hodgkin’s
lymphoma (NHL) (SIR¼0.93, 95% CI¼0.80–1.06, n¼188 vs
SIR¼1.42, 95% CI¼1.23–1.64, n¼202). In contrast, significantly
elevated SIRs that were higher for the shorter follow-up period
were observed for cancers of the endometrium (SIR¼1.65,
95% CI¼1.53–1.78, n¼671 vs SIR¼1.35, 95% CI¼1.21–1.50,
n¼335) and central nervous system (SIR¼1.25, 95% CI¼1.10–
1.41, n¼254 vs SIR¼1.00, 95% CI¼0.82–1.20, n¼113).
The effect of calendar period (1958–1979 vs 1980–2000) of
breast cancer diagnosis was also studied (data not shown). In order
to restrict the problem with truncation, the risk was estimated only
for follow-up periods 1–9 and 10–14 years after breast cancer
diagnosis. There were no apparent differences in risk by calendar
period, even after taking time since breast cancer diagnosis into
consideration, except for endometrial cancer where the risk in
those followed for 10–14 years was higher for the later (SIR¼1.67,
95% CI: 1.32–2.06, n¼77) compared to the earlier (SIR¼1.25,
95% CI: 0.99–1.54, n¼79) period.
Standardised incidence ratios stratified by age (o50 and 450
years) for selected sites with a significantly elevated overall SIR and at
least 100 observed cancers are presented in Table 2. Standardised
incidence ratios were also calculated separately for subcategories of
leukaemia and for connective tissue cancers in the thorax or upper
limbs, areas more likely to be in the radiation treatment field. For
most cancers, the risk decreased with increasing age at breast cancer
diagnosis, the higher risk ratio for younger compared to older women
for cancers at all sites combined being 1.36. Cancer sites where the
significant ratio was higher than 1.50 were oesophagus (ratio 1.84),
stomach (ratio 1.65), pancreas (ratio 1.51), lung (ratio 2.07), ovary
(ratio 1.82), thyroid (ratio 1.62), and connective tissue (ratio 2.21),
particularly thorax and upper limbs (ratio 2.32). A significantly
higher risk of leukaemia (reflecting the patterns observed for acute
and chronic myeloid leukaemia) was seen in younger compared to
older women 1–9 years after diagnosis of breast cancer (SIR¼2.86,
95% CI¼1.90–4.02, n¼28 vs SIR¼1.28, 95% CI¼1.10–1.47,
n¼185; ratio¼2.23), but this difference diminished in the later
follow-up period (SIR¼1.38, 95% CI¼0.95–1.94, n¼33 vs
SIR¼1.33, 95% CI¼1.08–1.63, n¼97; ratio¼1.04). A similar
pattern was seen for connective tissue cancer (SIR¼4.72, 95%
CI¼2.92–6.95, n¼21 vs SIR¼1.19, 95% CI¼0.88–1.56, n¼48;
ratio¼3.97), particularly of the thorax and upper limbs (SIR¼11.11,
95% CI¼5.51–18.65, n¼11 vs SIR¼2.79, 95% CI¼1.77–4.05,
n¼23; ratio¼3.98). For endometrial cancer, a statistically higher
risk for older compared to younger women (SIR¼1.15, 95%
CI¼0.86–1.47, n¼55 vs SIR¼1.72, 95% CI¼1.59–1.86, n¼616;
ratio 0.67) was observed in the 1- to 9-year follow-up period.
Risks of second primary cancers for women with and without
a family history of breast cancer are presented in Table 3.
Significantly higher risks analysed as a ratio between women with
and without a family history were seen for cancer of the
oesophagus, stomach, ovary, NHL, and leukaemia. The highest
SIRs were seen for second primary cancers of the oesophagus
(SIR¼7.54, 95% CI¼2.38–15.60, n¼5) and NHL (SIR¼6.10,
95% CI¼3.67–9.16, n¼19) among women with a family history
in the X10 year follow-up period. Their respective ratios
comparing women with and without a family history were
statistically significant (5.89 and 4.33).
DISCUSSION
Multiple malignancies may reflect increased surveillance, previous
therapy, shared aetiological (e.g. lifestyle) factors, and genetic
Table 1 Number of observed second primary cancers (Obs) following
breast cancer, diagnosed between 1958 and 2000, standardised incidence
ratios (SIRs), and 95% confidence interval (CI) among women
Second primary cancer site Obs SIR 95% CI
Upper aerodigestive tract 137 0.89 (0.75–1.04)
Salivary glands 43 1.67 (1.21–2.20)
Oesophagus 116 1.57 (1.24–1.78)
Stomach 686 1.40 (1.30–1.51)
Small intestine 76 1.29 (1.02–1.60)
Colorectum 1923 1.15 (1.10–1.20)
Liver 451 0.92 (0.84–1.01)
Pancreas 471 1.12 (1.02–1.22)
Lung 717 1.37 (1.27–1.47)
Cervix 217 0.92 (0.80–1.05)
Endometrium 1006 1.54 (1.44–1.63)
Ovary 712 1.28 (1.19–1.38)
Kidney 443 1.31 (1.19–1.44)
Urinary organs 383 1.10 (0.99–1.21)
Melanoma 360 1.27 (1.14–1.40)
Nervous system 367 1.16 (1.05–1.28)
Thyroid 164 1.55 (1.32–1.80)
Endocrine glands 270 1.08 (1.96–1.22)
Bone 21 1.68 (1.04–2.48)
Connective tissue 129 1.78 (1.49–2.10)
Non-Hodgkin’s lymphoma 390 1.13 (1.02–1.25)
Hodgkin’s disease 38 1.05 (0.74–1.41)
Multiple myeloma, plasmocytoma 182 1.04 (0.89–1.20)
Leukaemia 343 1.37 (1.23–1.52)
All the above sites 9758 1.22 (1.19–1.24)
Bold denotes statistical significance.
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family history of breast cancer, time since breast cancer, and their
interaction, we aimed to explore the aetiology of second primary
malignancies.
In our study, the SIRs for radiation-related solid tumours (e.g.
oesophagus, lung, NHL, and connective tissue, particularly thorax
and upper limbs) were higher in the 10 or more years follow-up
period, whereas leukaemia risk was similar for both time periods.
Women diagnosed before the age of 50 years had a substantially
higher risk for all cancer sites (except the endometrium, central
nervous system, acute and chronic lymphatic leukaemia, and
melanoma), possibly due to increased susceptibility as well as
more aggressive treatment for breast cancer in younger women.
Increased risks analysed as the ratio between women with and
without a family history of breast cancer were seen in cancers of
the oesophagus, stomach, ovary, NHL, and leukaemia.
Table 2 Number of observed second primary cancers (Obs) following breast cancer, diagnosed between 1958 and 2000, standardised incidence ratios
(SIRs), and 95% confidence interval (CI) for second primary malignancy according to age at breast cancer diagnosis
Age at breast cancer diagnosis
o50 years X50 years
Second primary cancer site Obs SIR 95% CI Obs SIR 95% CI Ratio
Oesophagus 20 2.54 (1.55–3.78) 96 1.38 (1.12–1.67) 1.84*
Stomach 97 2.18 (1.77–2.63) 589 1.32 (1.22–1.43) 1.65*
Colorectum 278 1.38 (1.23–1.58) 1645 1.12 (1.06–1.17) 1.24*
Pancreas 74 1.60 (1.26–1.99) 397 1.06 (0.96–1.16) 1.51*
Lung 235 2.35 (2.06–2.66) 482 1.14 (1.04–1.24) 2.07*
Endometrium 183 1.29 (1.11–1.49) 823 1.61 (1.50–1.72) 0.80*
Ovary 247 1.97 (1.73–2.22) 465 1.08 (0.98–1.18) 1.82*
Kidney 74 1.50 (1.18–1.86) 369 1.28 (1.15–1.41) 1.17
Melanoma 91 1.32 (1.06–1.61) 269 1.25 (1.10–1.40) 1.06
Nervous system 89 1.25 (1.00–1.52) 278 1.14 (1.01–1.27) 1.10
Thyroid 51 2.21 (1.65–2.86) 113 1.36 (1.12–1.63) 1.62*
Endocrine glands 75 1.36 (1.07–1.68) 195 1.01 (0.87–1.15) 1.35*
Connective tissue 40 3.27 (2.33–4.36) 89 1.48 (1.19–1.80) 2.21*
Thorax and upper limbs 19 8.02 (4.82–12.03) 42 3.46 (2.49–4.58) 2.32*
Non-Hodgkin’s lymphoma 77 1.51 (1.19–1.87) 313 1.06 (0.95–1.19) 1.42*
Leukaemia 61 1.81 (1.38–2.29) 282 1.30 (1.15–1.46) 1.39*
Acute lymphatic leukaemia 2 1.20 (0.14–3.45) 20 2.19 (1.34–3.26) 0.55
Chronic lymphatic leukaemia 14 1.15 (0.63–1.84) 87 0.96 (0.77–1.17) 1.21
Acute myeloid leukaemia 22 1.97 (1.23–2.88) 91 1.46 (1.17–1.77) 1.35
Chronic myeloid leukaemia 13 2.89 (1.53–4.67) 33 1.56 (1.08–2.14) 1.85
All the above sites 1692 1.64 (1.56–1.72) 6405 1.20 (1.17–1.23) 1.36*
Standardised incidence ratio for women o50 years of age at breast cancer diagnosis was compared with SIR for women X50 years of age at breast cancer diagnosis (ratio). Bold
denotes statistical significance; * denotes statistically significant ratio.
Table 3 Number of observed second primary cancers (Obs) following breast cancer, diagnosed between 1958 and 2000, standardised incidence ratios
(SIRs), and 95% confidence interval (CI) for second primary malignancy according to family history of breast cancer
Family history of breast cancer
Yes No
Second primary cancer site Obs SIR 95% CI Obs SIR 95% CI Ratio
Oesophagus 7 3.76 (1.49–7.07) 58 1.69 (1.29–2.16) 2.22*
Stomach 27 2.65 (1.74–3.74) 296 1.41 (1.26–1.58) 1.88*
Colorectum 46 1.10 (0.81–1.45) 1010 1.18 (1.11–1.25) 0.93
Pancreas 9 0.86 (0.39–1.52) 253 1.18 (1.04–1.33) 0.73
Lung 16 0.91 (0.52–1.41) 483 1.45 (1.32–1.58) 0.63
Endometrium 41 1.94 (1.39–2.58) 589 1.45 (1.34–1.57) 1.33
Ovary 40 2.32 (1.66–3.10) 437 1.38 (1.25–1.51) 1.68*
Kidney 8 0.89 (0.38–1.61) 239 1.29 (1.14–1.46) 0.69
Melanoma 18 1.67 (1.00–2.53) 231 1.28 (1.12–1.45) 1.31
Nervous system 13 1.20 (0.63–1.94) 236 1.25 (1.09–1.41) 0.96
Thyroid 5 1.51 (0.48–3.12) 104 1.78 (1.46–2.14) 0.85
Endocrine glands 12 1.37 (0.70–2.25) 199 1.19 (1.03–1.36) 1.15
Connective tissue 5 2.48 (0.78–5.12) 79 2.06 (1.63–2.54) 1.20
Non-Hodgkin’s lymphoma 23 2.41 (1.52–3.49) 231 1.13 (0.99–1.28) 2.13*
Leukaemia 19 2.25 (1.35–3.38) 218 1.29 (1.13–1.47) 1.74*
All the above sites 289 1.58 (1.40–1.77) 4663 1.31 (1.27–1.35) 1.21*
Standardised incidence ratio for women with family history of breast cancer was compared with SIR for women without family history of breast cancer (ratio). Bold denotes
statistical significance; * denotes statistically significant ratio.
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in women with a family history of breast cancer compared to
women without a family history of breast cancer X10 years
following breast cancer diagnosis (SIR¼7.54 vs 1.28) suggests an
interaction between radiotherapy and inherited factors. In earlier
studies, a high familial risk was found (Czene et al, 2002; EBCTCG,
2005). In addition, environmental factors such as tobacco and
alcohol are important for oesophageal cancer and probably explain
part of the familial clustering, although this could be due to
chance, because the study was based on only five cases.
We found an increased risk of stomach cancer, which was
significantly higher in women diagnosed with breast cancer before
50 and in women with a family history of breast cancer, suggesting
a role of shared environmental and genetic factors. Rare syndromes
such as Li–Fraumeni syndrome and ataxia telangiectasia can
explain little of the elevated risk (Bevan and Houlston, 1999).
As in other studies (Neugut et al, 1994) and consistent with the
effects of radiotherapy, risks of lung cancer were greater with
longer follow-up time and younger age at breast cancer diagnosis.
We recently reported an interaction between ionising radiation
and smoking in women with breast cancer where the risk of lung
cancer was confined to smokers who received radiotherapy
(Prochazka et al, 2005).
We found the highest risk of endometrial cancer among women
aged 50 or older at breast cancer diagnosis in the 1–9 year follow-
up period. Our age and temporal findings (risk was higher during
the later study period, 1980–2000) are consistent with the effects of
tamoxifen treatment starting in the late 1970s in women over age
50 (Bergman et al, 2000; Swerdlow and Jones, 2005). An increased
risk of breast cancer after endometrial cancer has also been
reported (Mellemkjaer et al, 2006). Shared risk factors such as
early menarche, late menopause, and nulliparity (Bergman et al,
2000) probably also contributed to our findings.
BRCA-1 and BRCA-2 genes are known to be involved in inherited
susceptibility to breast and ovarian cancer (Lindor and Greene,
1998; Welcsh and King, 2001) and may contribute to the 1.8-fold
higher risk of second ovarian cancer we observed in women
diagnosed with breast cancer at younger ages as well as the 1.7-fold
higher risk in women with a family history of breast cancer
compared with those without a family history of breast cancer.
We found an increased risk of melanoma for women with a
family history of breast cancer, suggesting genetic influence. A
number of studies have suggested mutations of CDKN2A and
BRCA2 as possible determinants of the higher incidence of
melanoma among breast cancer patients (Borg et al, 2000; Goggins
et al, 2004).
We found a higher overall risk of a connective tissue malignancy
with a longer follow-up time. However, when age and time since
breast cancer diagnosis were considered jointly, an almost five-fold
risk was observed in women o50 years old within the first 10 years
following breast cancer diagnosis. The risk was even more
pronounced in connective tissue cancers of the thorax or upper
limbs, parts often included in the radiation field during breast
cancer treatment, as previously reported (Harvey and Brinton,
1985; Kirova et al, 2005).
In agreement with previous reports, we found that the risk of
NHL increased with time (Harvey and Brinton, 1985). In our study,
the risk X10 years after breast cancer diagnosis was four times
higher in women with a family history of breast cancer compared
to those without a family history, suggesting possible interaction of
treatment with genetic factors.
A review (van Leeuwen and Travis, 2001) as well as later work
(Smith et al, 2003; Raymond and Hogue, 2006) reported that
alkylating agents/radiotherapy increased the risk of leukaemia
beginning 1–2 years following treatment and peaking at 5–10
years after treatment, consistent with our results. We also found an
elevated risk of leukaemia in women with a family history of breast
malignancy.
The strengths of our study are the population-based design,
complete follow-up of all patients, and the ability to identify
women with a family history of breast cancer. We excluded
malignancies diagnosed during the first year of follow-up avoiding
detection of indolent tumours by increased surveillance. Among
limitations we could not identify potential treatment effects
because therapy information is not recorded in the cancer register.
In conclusion, we found that women diagnosed with breast
cancer had a 22% increased risk of developing a second primary
non-breast malignancy. Women with breast cancer before age 50
and women with a family history of breast cancer had elevated
risks of developing several cancers, indicating a genetic predis-
position to develop multiple tumours and/or susceptibility to the
carcinogenic effect of breast cancer therapy.
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